hydroxyzine hydrochloride / Generic mfg. - LARVOL DELTA

APHYPAP: Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms (clinicaltrials.gov) - P3 | N=63 | Completed | Sponsor: University Hospital, Brest | Recruiting ➔ Completed

Trial completion • Dermatology • Myeloproliferative Neoplasm • Oncology • Pruritus

Post-lanosterol inhibition profile based classification of commonly used prescription medications. (PubMed, Transl Psychiatry) - "Using LC-MS/MS we measured 13 post-lanosterol intermediates in control, DHCR7 +/- and DHCR7-/- human dermal fibroblasts exposed to cariprazine, nebivolol, rotigotine, buspirone, lurasidone, fluoxetine, hydroxyzine, amiodarone, spiroxamine, vilazodone and ziprasidone. In addition, DHCR7 +/- fibroblasts responded with greater sterol profile disruptions to all medications, while DHCR7 fibroblasts from patients with Smith-Lemli-Opitz syndrome showed generally a more plateaued response. Knowing the inhibition profile-based classification of medications that have a sterol inhibiting side effect might ultimately translate into safety recommendations during pregnancy and could be critical for new drug development."

Journal • DHCR7

Impact of atropine and hydroxyzine pretreatment in contemporary bronchoscopy. (PubMed, Respir Investig) - "Anticholinergic pretreatment may reduce procedural discomfort, particularly that associated with secretions and airway reflexes, without evident adverse effects. Further randomized controlled trials are required to validate the role of pretreatment in contemporary bronchoscopy."

Journal • Cough • Respiratory Diseases

Treatment-Resistant Eosinophilic Spongiosis Dermatitis in a Patient With Various Comorbidities: A Case Report. (PubMed, Cureus) - "Alongside receiving a thorough cardiovascular exam workup, the patient tried numerous treatments for his rash and the pruritus, including topical triamcinolone, tacrolimus ointment, steroid injections, hydroxyzine, amitriptyline, and, most recently, dupilumab therapy. This case report highlights the complexity of ongoing assessment and treatment, offering guidance for the care of patients with similar presentations. Educational insights obtained from this report include maintaining broad differential diagnoses, the influence of neuropsychiatry and cardiology in dermatology, and the importance of multidisciplinary care."

Journal • Atopic Dermatitis • Cardiovascular • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Mood Disorders • Pain • Pruritus • Psychiatry • Pulmonary Disease • Venous Ulcer

EGLN1-Positive Familial Erythrocytosis: A Rare Variant with an Unusually Aggressive Clinical Course (ASH 2024) - "These symptoms do not respond to cimetidine or hydroxyzine but are partially controlled to HCT targets well below 45%, with the best symptom relief at 38-40%.Furthermore, he has subsequently developed idiopathic inflammatory polyarthritis and interstitial pulmonary disease with exhaustive work up by rheumatology and pulmonology, respectively, returning negative for specific cause.ConclusionsThis case is the first clinical characterization of EGLN1 c.494del p(Pro165Glnfs*9) positive familial erythrocytosis. His refractory symptoms despite optimal hematologic control suggest that HCT level may be an inadequate indicator of disease control in familial erythrocytosis. As recognition, awareness, and testing of congenital JAK2 negative erythrocytosis increases, further research is needed to characterize the genotype and phenotype correlation for variants of this rare condition."

Clinical • Cardiovascular • Dermatology • Dyslipidemia • Fatigue • Fibrosis • Hematological Disorders • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Metabolic Disorders • Polycythemia Vera • Pruritus • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Rheumatology • Thrombosis • Venous Ulcer • CALR • EGLN1 • JAK2

Use of Dupilumab in the Treatment of Bullous Pemphigoid with Type 2 Inflammatory Phenotype (ACAAI 2025) - "Initial treatment with topical corticosteroids, hydroxyzine, and loratadine was ineffective...Combination therapy with methotrexate, rituximab, and prednisone initially controlled symptoms, but flared again during tapering. The patient was subsequently initiated on dupilumab 300 mg subcutaneously every two weeks, resulting in complete clinical remission and successful steroid discontinuation. Discussion This case highlights the potential role of dupilumab as a safe and effective corticosteroid-sparing option for treatment of bullous pemphigoid in patients with a type 2 inflammatory phenotype."

Allergic Rhinitis • Atopic Dermatitis • Bullous Pemphigoid • Dermatology • Dermatopathology • Eosinophilia • Immunology • Inflammation • IL13 • IL4R

Rituximab-Induced Serum Sickness: Clinical Clues And Management Insights (ACAAI 2025) - "Infectious workup was negative and she was discharged with hydroxyzine and topical diphenhydramine...RISS was diagnosed and high-dose IV methylprednisolone was initiated, inducing rapid improvement...It can also mimic infection, leading to hospitalizations and necessitating a multidisciplinary approach. Given the high risk of recurrence with challenge or desensitization, obinutuzumab may be considered for alternative B-cell depleting therapy."

Clinical • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Musculoskeletal Pain • Renal Disease • IL6

Dual Biologic Therapy For Refractory Autoimmune Chronic Urticaria (ACAAI 2025) - "We present a case of autoimmune CSU refractory to guideline-recommended therapies, which ultimately required dual therapy with omalizumab and dupilumab to achieve symptom control...She did not respond to multiple first (hydroxyzine, doxepin) and second-generation antihistamines (cetirizine, loratadine, levocetirizine), as well as montelukast, and required intermittent corticosteroids during severe flares...She remains on the current regimen with tentative plans to first taper omalizumab prior to its discontinuation. Discussion This case highlights the potential for dual biologic therapy for treatment-resistant autoimmune chronic spontaneous urticaria."

Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Knowledge, Attitudes, and Practices of Dermatologists on Chronic Pruritus and Its Management. (PubMed, Cureus) - "Hydroxyzine and its sustained-release formulation were regarded as convenient and effective, supporting simplified dosing and better adherence. Strengthening patient education remains essential to optimizing CP management."

Journal • Dermatology • Pruritus

Influenza A-Induced Acute Liver Injury: A Rare Adverse Effect (ACG 2025) - "The patient's home medications include atorvastatin, carbamazepine, cyclobenzaprine, famotidine, fluoxetine, gabapentin, hydroxyzine, metformin, multivitamin, propranolol, senna, Seroquel, vitamin B1, Vivitrol. Additionally, labs from a month ago showed liver enzymes to be at baseline. These findings along with the IVA infection point towards IAV-induced ALF.Given the potential for ALI, especially in severely ill patients, routine liver enzyme testing is recommended in the management of IAV infection."

Adverse events • Autoimmune Hepatitis • Chronic Kidney Disease • Hepatology • Immunology • Infectious Disease • Inflammation • Influenza • Liver Failure • Metabolic Disorders • Respiratory Diseases

Acneiform Eruption Following Transition From Intravenous to Subcutaneous Vedolizumab Injection in a Patient With Crohn's Disease (ACG 2025) - "Treatment with oral doxycycline, topical clindamycin, and hydroxyzine led to partial resolution within two weeks. Early recognition of this uncommon reaction can prevent prolonged discomfort and allow alternative strategies for the continued management of inflammatory bowel disease. This abstract was prepared with the assistance of a generative AI tool.Figure: Multiple erythematous papules and pustules on the forehead, chin, and cheeksFigure: Complete resolution of the facial lesions after the course of oral and topical antibiotics"

Clinical • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Neutropenia • Ulcerative Colitis

Extraordinary Response to Odevixibat in an Adult Patient With Progressive Familial Intrahepatic Cholestasis Type 1 and Intractable Pruritus: A Case Report (ACG 2025) - "He had poor response to prior therapeutic measures including cholestyramine, ursodiol, sertraline, hydroxyzine, rifampin, and topical steroids. Hence, odevixibat should be considered as an option for refractory pruritus in adult patients with PFIC type 1.Figure: Table 1. Liver tests before (blue) and after (green) initiation of Bylvay (odevixibat)."

Case report • Clinical • Cholestasis • Dermatology • Fibrosis • Hepatology • Immunology • Liver Failure • Pruritus

Scratching the Surface: Successful Treatment of Severe Intrahepatic Cholestasis of Pregnancy With an Ileal Bile Acid Transporter Inhibitor (IBAT) (ACG 2025) - "Current standard of care include treatment with ursodeoxycholic acid (UDCA) which may be insufficient in severe cases...She was started on UDCA, cholestyramine and hydroxyzine...Despite maximal doses of UDCA, she continued to have worsening pruritus and rising BA with peak of 364 µmol/L in her third trimester.After discussion with maternal fetal medicine, she received Odevixibat though expanded access...While further study is needed, our case report demonstrated improvement in pruritus and serum BA in our patient with refractory ICP. This supports the need for potential for IBAT inhibitors as adjunctive therapy in select, high-risk ICP patient unresponsive to conventional therapy."

Cholestasis • Dermatology • Fibrosis • Gynecology • Hepatology • Immunology • Infectious Disease • Inflammation • Pruritus • ABCB1

ANTITUBERCULAR THERAPY-INDUCED DRESS SYNDROME: A RARE BUT LIFE-THREATENING ADVERSE REACTION (CHEST 2025) - "Now ATT was stopped and patient is started on prednisolone (30 mg/day for 10 days), levocetirizine (5 mg/day for 10 days), atarax (10 mg/day for 5 days) and topical paraffin oil...The patient was then started on modified ATT regimen consisting isoniazid (300 mg), levofloxacin (750 mg), and linezolid (600 mg twice daily) for 6 months... Clinicians from high TB burden countries must be aware of DRESS associated with ATT. Timely management is vital as it is associated with 10% mortality and should be differentiated from other skin reactions.This case highlights the importance of recognizing DRESS syndrome as a rare but potentially life-threatening adverse reaction to ATT an emphasizes the need for early diagnosis and prompt intervention."

Dermatitis • Dermatology • Eosinophilia • Hepatology • Immunology • Inflammation • Nephrology • Pneumonia • Pruritus • Pulmonary Disease • Respiratory Diseases • Steven-Johnson Syndrome

THE EMERGENCE OF "TRANQ DOPE": A XYLAZINE CASE SERIES (CHEST 2025) - "She was difficult to extubate due to severe agitation requiring multiple drips including Midazolam, Dexmedetomidine, Ketamine, and Propofol...A 33 year old female with a past medical history of polysubstance abuse including cocaine, fentanyl, xylazine, and heroin on methadone was admitted to the ICU for septic shock secondary to methicillin-resistant Staph aureus leg wounds...Her drug withdrawal was treated with Dexmedetomidine, clonidine, hydroxyzine, methadone, and as needed lorazepam and haloperidol... Xylazine is a growing health concern as it presents new challenges to practitioners. Healthcare providers need to be aware of xylazine, and the unique symptoms patients may present with. Identification of these patients will expedite appropriate care."

Clinical • Addiction (Opioid and Alcohol) • Anesthesia • Asthma • Cardiovascular • Fibrosis • Gastroenterology • Hepatitis C • Hepatology • Hypertension • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Respiratory Diseases • Septic Shock

Alignment of Sedation Training and Current Practices in Pediatric Dentistry. (PubMed, Pediatr Dent) - "Predominant sedation medication preferences have shifted from chloral hydrate to midazolam, meperidine, and hydroxyzine through the years. Feedback from previous learners and continual assessment of educational programs can help to align education with unsupervised practice after graduation. Changing trends in sedation practices highlight the crucial significance that residency program sedation curriculum and continuing education courses meet the needs of patients, thereby upholding a high standard of patient safety."

Journal • Anesthesia • Pediatrics

ASSOCIATION BETWEEN PRURITUS AND HEALTHCARE UTILIZATION AND COSTS AMONG INDIVIDUALS WITH PRIMARY BILIARY CHOLANGITIS IN THE UNITED STATES (AASLD 2025) - "Subgroup analyses required pruritus treatment (sertraline, naltrexone, cholestyramine, cholestipol, rifampin, colesevelam, hydroxyzine or diphenhydramine) within ±90 days of the index date. Eligibility included age >=18, continuous enrollment for >=12 months pre- and post-index date, excluding patients receiving obeticholic acid during baseline... In a real-world study of patients with PBC, pruritus was a significant contributor to HCRU and costs. These findings highlight the need for effective management and novel therapies to alleviate pruritus and reduce its associated clinical burden and costs."

Clinical • HEOR • Alzheimer's Disease • CNS Disorders • Dementia • Depression • Dermatology • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus • Psychiatry • Sleep Disorder

Anesthesia and Analgesia in a parturient patient with sickle cell crisis (ASA 2025) - "A comprehensive pain management approach, including hydromorphone PCA, buprenorphine, and epidural analgesia, was implemented. She developed preeclampsia, protracted labor, and required an emergency cesarean section under general anesthesia with fentanyl, ketamine, propofol, succinylcholine, and 4 units of PRBC transfused. Postoperative headaches and tachycardia were treated with hydroxyzine. Enoxaparin was given for venous thromboembolism prevention. This case underscores the importance of multidisciplinary care in managing complex pain and pregnancy complications in SCD patients."

Clinical • Anesthesia • Cardiovascular • Genetic Disorders • Gynecology • Hematological Disorders • Sickle Cell Disease • Venous Thromboembolism

LIVER ELASTOGRAPHY IN PEDIATRIC PATIENTS WITH ALAGILLE SYNDROME RECEIVING MARALIXIBAT THERAPY: A REAL-WORLD SINGLE-CENTER STUDY (AASLD 2025) - "All patients had previously been treated with ursodeoxycholic acid, rifampicin, hydroxyzine, and fat-soluble vitamins, which were continued during the study. In this real-world cohort study, children with ALGS who responded to Maralixibat and improved pruritus and serum bile acid levels, showed a favorable trend of decreasing values in liver elastography over time. Although the sample size is small, the effect of Maralixibat seems promising on mitigating disease progression and merits further investigation with recruitment of more patients and a longer follow-up period."

Clinical • Real-world • Real-world evidence • Cholestasis • Dermatology • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Pediatrics • Pruritus

EPIDEMIOLOGICAL AND GENETIC CHARACTERISTICS OF CHILDREN WITH ALAGILLE SYNDROME: A SINGLE-CENTRE EXPERIENCE FROM BRAZIL (AASLD 2025) - "Medications used were ursodeoxycholic acid, rifampicin, sertraline, cholestyramine and hydroxyzine. This study highlights the variability of clinical features and multisystem involvement in ALGS. Neonatal cholestasis, pruritus, typical facies, and cardiac anomalies were frequent. The findings reinforce the need for early recognition and multidisciplinary care."

Clinical • Alzheimer's Disease • Cardiovascular • Cholestasis • Cognitive Disorders • Dermatology • Fibrosis • Heart Failure • Hepatology • Immunology • Ophthalmology • Pruritus • Renal Disease • JAG1 • NOTCH2

ILEAL BILE ACID TRANSPORTER INHIBITORS FOR REFRACTORY PRURITUS IN LIVER TRANSPLANT RECIPIENTS: A CASE SERIES (AASLD 2025) - "Ileal bile acid transporter (IBAT) inhibitors, such as odevixibat and maralixibat, have demonstrated efficacy in treating cholestatic pruritus in other contexts but remain underexplored in the post-LT setting...She continued hydroxyzine and doxepin as needed but reports improved quality of life... IBAT inhibitors may represent a safe and effective option for managing refractory pruritus in liver transplant recipients, with potential benefits extending beyond symptom control to meaningful improvements in quality of life. Importantly, these agents were well-tolerated and did not disrupt immunosuppressive regimens or graft function. Given the significant burden of post-LT pruritus and the limited efficacy of existing treatments, further prospective studies are warranted to evaluate long-term safety, efficacy, and optimal clinical use of IBAT inhibitors in this population."

Clinical • Dermatology • Pruritus • Transplant Rejection • Transplantation

Pigmentary Maculopathy in Patients with Interstitial Cystitis: Association with Pentosan Polysulfate and Other Therapies. (PubMed, Ophthalmol Sci) - "Patients with PPS exposure had increased odds of exposure to hydroxyzine (odds ratio [OR]: 4.76, P < 0.0001), amitriptyline (OR: 2.62, P < 0.0002), phenazopyridine or pyridium (OR: 1.68, P = 0.036), narcotics (OR: 2.68, P < 0.0001), oxybutynin (OR: 1.93, P = 0.041), cystoscopy with hydrodistention (OR: 4.001, P < 0.0001), bladder instillation (OR: 6.83, P < 0.0001), and vaginal valium (OR: 9.515, P = 0.033). Concurrent exposure to PPS and amitriptyline/nortriptyline or cyclosporine may increase the risk of developing maculopathy but these results should be validated by larger prospective studies. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • Interstitial Cystitis • Macular Degeneration • Retinal Disorders

Case report. Job syndrome as an unusual finding in a pediatric patient (PubMed, Rev Alerg Mex) - "The therapeutic strategy focuses on the prevention and management of infections and symptoms. It is important to identify complications in the early stages of the disease to treat them effectively. This syndrome, although rare, should be considered a serious condition; early identification of this condition is crucial to improve outcomes in patients with similar presentations."

Journal • Asthma • Atopic Dermatitis • Bone Marrow Transplantation • Dermatitis • Dermatology • Eosinophilia • Immunology • Infectious Disease • Musculoskeletal Diseases • Pediatrics • Primary Immunodeficiency • Pulmonary Disease • Respiratory Diseases • Transplantation

Clinical patterns of pruritus in epidermolysis bullosa: an observational study (EADV 2025) - "Various therapies have been explored, from topical agents to systemic antihistamines and immunomodulators, with dupilumab emerging as a promising new option...All patients were managed with cool compresses/ wet wraps, topical steroids/ tacrolimus, and antihistamines (cetirizine/ hydroxyzine)... Significant pruritus was reported in nearly all EB cases, regardless of subtype. Itch typically began in late infancy and improved in older children. Summer exacerbations were common."

Clinical • Observational data • Dermatology • Infectious Disease • Pruritus

Lamellar Ichthyosis in a 3-Year-Old Child: A Case Report (EADV 2025) - "On the scalp, ketoconazole shampoo 20 mg/mL is used on alternate days. The patient has been receiving acitretin at a dose of approximately 0,9 mg/kg/day, along with a first-generation oral antihistamine (hydroxyzine hydrochloride, syrup)... Lamellar ichthyosis is a challenging condition for the healthcare team during the neonatal period, requiring intensive care. As there is no cure, it is essential to provide multidisciplinary follow-up, focusing on dermatology, pediatrics, and ophthalmology. Genetic counseling is important, as well as fostering a good physician-patient- family relationship."

Case report • Clinical • Alopecia • Atopic Dermatitis • Dermatology • Dermatopathology • Immunology • Keratitis • Ocular Inflammation • Ophthalmology • Pediatrics • Pruritus • Rare Diseases • Vitiligo